American Society of Hematology Annual Meeting

Investigational Oral Chemotherapy Boosts Survival in Older Patients with AML

December 11th 2019, 1:00am

Article

Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.

Genomic Sequencing Could Individualize Diagnosis, Treatment of Myeloid Cancers

December 10th 2019, 11:00pm

Article

Whole genome sequencing of blood and bone marrow from patients with acute myeloid leukemia and myelodysplastic syndrome has revealed previously unknown disease subtypes.

Immunotherapy Is Superior to Chemotherapy for Children and Young Adults with Relapsed B-Acute Lymphoblastic Leukemia

December 10th 2019, 7:00pm

Article

In a phase 3 clinical trial, Blincyto (blinatumomab), a type of immunotherapy, improved survival and showed fewer side effects in young patients.

Ibrutinib and Rituximab Improve Progression-Free Survival for Patients with CLL

December 10th 2019, 1:00am

Article

Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

Clinical Trial Data Highlights Stark Socioeconomic Disparities in Survival Rates Among Children with AML

December 8th 2019, 11:00pm

Article

New findings show that the socioeconomic status of children with AML plays a significant and alarming roll in the rate of their overall survival after diagnosis.

African American Patients Unnecessarily Excluded From AML Clinical Trials

December 8th 2019, 9:00pm

Article

Baseline laboratory values for AML clinical trials are setting unnecessary restrictions for kidney function that excludes African American patients with AML when this comorbidity does not impact overall survival.

Mosunetuzumab Produces Complete Remissions in Patients with Non-Hodgkin Lymphoma

December 8th 2019, 6:00pm

Article

Some patients with non-Hodgkin lymphoma may soon have a treatment option that could offer complete remission, according to new data presented at the American Society of Hematology 2019 Annual Meeting.

CAR-T Cell Therapy That Targets Two Proteins May Help Patients with Multiple Myeloma

December 8th 2019, 1:18am

Article

A dual-targeted chimeric antigen receptor-T cell therapy showed a more than 90% overall response rate in patients with relapsed or refractory disease.

Early Study Findings Lead to FDA Breakthrough Therapy Designation for CAR-T Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma

December 7th 2019, 10:36pm

Article

JNJ-4528 showed deep responses and proved to be safe in patients with multiple myeloma, according to CARTITUDE-1 study findings.